The REACTION study presented at the ASH Annual Meeting and Exposition showed that ravulizumab maintained control of intravascular hemolysis and stable hemoglobin levels in patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab. The study included 80 patients who switched from eculizumab to ravulizumab. Researchers observed a decrease in breakthrough hemolysis events and transfusion needs with ravulizumab compared to eculizumab. Overall, the study confirmed the safety and efficacy of ravulizumab in controlling hemolysis and maintaining stable hemoglobin levels in patients with PNH. No new adverse events were reported during the study.
Source link